全文获取类型
收费全文 | 221篇 |
免费 | 23篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 10篇 |
妇产科学 | 3篇 |
基础医学 | 22篇 |
口腔科学 | 5篇 |
临床医学 | 17篇 |
内科学 | 27篇 |
皮肤病学 | 2篇 |
特种医学 | 25篇 |
外科学 | 16篇 |
综合类 | 6篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 9篇 |
肿瘤学 | 99篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 7篇 |
2013年 | 13篇 |
2012年 | 5篇 |
2011年 | 5篇 |
2010年 | 10篇 |
2009年 | 10篇 |
2008年 | 9篇 |
2007年 | 9篇 |
2006年 | 6篇 |
2005年 | 10篇 |
2004年 | 15篇 |
2003年 | 5篇 |
2002年 | 12篇 |
2001年 | 15篇 |
2000年 | 5篇 |
1999年 | 6篇 |
1998年 | 5篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有246条查询结果,搜索用时 51 毫秒
51.
Obstructive jaundice secondary to benign hepatic cyst 总被引:1,自引:0,他引:1
A case of hepatic cyst causing obstructive jaundice is presented. Following percutaneous aspiration of the cyst, the jaundice was relieved. Modern interventional radiologic techniques can provide prompt diagnosis and treatment, thus avoiding major surgery and prolonged hospitalization. 相似文献
52.
53.
54.
Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis 总被引:1,自引:0,他引:1
Zhu M Saxton RE Ramos L Chang DD Karlan BY Gasson JC Slamon DJ 《Molecular cancer therapeutics》2011,10(8):1500-1508
Periostin, an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions seem to be linked to tumor metastasis. Our previous results show that engineered periostin overexpression promotes ovarian tumor growth and dissemination in vivo. In this study, we developed a neutralizing monoclonal antibody to periostin, named MZ-1, and investigated its effects on human ovarian tumor growth and metastasis. Our in vivo studies showed significant growth inhibition by MZ-1 on both subcutaneous and intraperitoneal (i.p.) tumors derived from the periostin-expressing ovarian cancer cell line A2780. In addition, MZ-1 treatment led to a reduction of the metastatic potential of these A2780 i.p. tumors. The in vivo antitumor effects of MZ-1 were linked to its specific inhibition of anchorage-independent growth and survival of periostin-expressing cells, as well as its neutralizing effects on periostin-induced cancer cell migration and invasion. The data suggest that blocking periostin expression may be a novel approach for treating the subset of invasive ovarian tumors that overexpress periostin protein. 相似文献
55.
56.
57.
Carolyn D. Britten Richard S. Finn Linda D. Bosserman Steven G. Wong Michael F. Press Mubashira Malik Bert L. Lum Dennis J. Slamon 《Clinical breast cancer》2009,9(1):16-22
BackgroundThis phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer.Patients and MethodsIn phase I, sequential groups of patients with unlimited previous treatment received erlotinib at dose levels of 50, 100, and 150 mg plus standard dose weekly trastuzumab. In phase II, only patients with no previous chemotherapy or trastuzumab in the metastatic setting were allowed.ResultsThe combination was well tolerated among the 16 patients enrolled in phase I, and the recommended phase II dose of erlotinib was initially set at 150 mg. After an interim review of the first 8 patients in phase II revealed a higher incidence of rash and diarrhea than expected from the phase I experience, the protocol was amended to treat new phase II patients at erlotinib 100 mg, with the opportunity to escalate to 150 mg after 3 weeks, based on individual patient tolerability. As a result of advances in other therapies aimed at HER2+ breast cancer, phase II closed before meeting its accrual goal. Among the 12 evaluable chemotherapy- and trastuzumab-naive patients treated at the recommended phase II dose level, there were 4 partial responses, and the time to progression was 9.03 months (95% CI, 1.2-undetermined). No pharmacokinetic interaction between the 2 agents was observed.ConclusionThe combination of erlotinib and trastuzumab was well tolerated when the dose of erlotinib was tailored to individual patient experience, and there was preliminary evidence of anticancer activity. 相似文献
58.
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells 总被引:1,自引:0,他引:1
Konecny GE Venkatesan N Yang G Dering J Ginther C Finn R Rahmeh M Fejzo MS Toft D Jiang SW Slamon DJ Podratz KC 《British journal of cancer》2008,98(6):1076-1084
In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of endometrial cancer. The effect of lapatinib on tumour cell growth and receptor activation was studied in a panel of human endometrial cancer cell lines. Candidate molecular markers predicting sensitivity were assessed by baseline gene expression profiling, ELISA, and western blot analyses. Multiple drug effect/combination index (CI) isobologram analysis was used to study the interactions between chemotherapeutic drugs and lapatinib. Concentration-dependent anti-proliferative effects of lapatinib were seen in all endometrial cancer cell lines tested, but varied significantly between individual cell lines (IC(50) range: 0.052-10.9 micromol). HER2 overexpression or increased expression of EGFR was significantly associated with in vitro sensitivity (P=0.024 or 0.011, respectively). Lapatinib exerts growth inhibition in a PTEN-independent manner. Sensitive cell lines also exhibited increased expression of EGFR ligands or HER3. In contrast, lapatinib-resistant cell lines exhibited high androgen receptor (AR) levels or epithelial-to-mesenchymal transition (post-EMT) features. In endometrial cancer cells, at a wide range of clinically achievable drug concentrations, additive and synergistic interactions were observed for lapatinib plus carboplatin, paclitaxel, docetaxel, and doxorubicin. These observations provide a clear biologic rational to test lapatinib as a single agent or in combination with chemotherapy in endometrial cancer with HER2 overexpression. Expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from lapatinib. 相似文献
59.
Huili Li Katherine B. Chiappinelli Angela A. Guzzetta Hariharan Easwaran Ray-Whay Chiu Yen Rajita Vatapalli Michael J. Topper Jianjun Luo Roisin M. Connolly Nilofer S. Azad Vered Stearns Drew M. Pardoll Nancy Davidson Peter A. Jones Dennis J. Slamon Stephen B. Baylin Cynthia A. Zahnow Nita Ahuja 《Oncotarget》2014,5(3):587-598
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidine (AZA). Gene Set Enrichment Analysis demonstrated significant enrichment for immunomodulatory pathways in all three cancers (14.4-31.3%) including interferon signaling, antigen processing and presentation, and cytokines/chemokines. Strong upregulation of cancer testis antigens was also observed. An AZA IMmune gene set (AIMs) derived from the union of these immunomodulatory pathway genes classified primary tumors from all three types into “high” and “low” AIM gene expression subsets in tumor expression data from both TCGA and GEO. Samples from selected patient biopsies showed upregulation of AIM genes after treatment with epigenetic therapy. These results point to a broad immune stimulatory role for DNA demethylating drugs in multiple cancers. 相似文献